No Detail Found!

Nedaplatin-induced Arrhythmia: Retrospective Analysis of Three Cases.

Author(s)
Ying Jie Song Department of General Surgery, Three Gorges University People's Hospital, The First People's Hospital of Yichang, Xiling District, Yichang City, Hubei, China
Tao Fan Department of Oncology, Three Gorges University People's Hospital, The First People's Hospital of Yichang, Xiling District, Yichang City, Hubei, China
Chang Yin Quan Department of General Surgery, Three Gorges University People's Hospital, The First People's Hospital of Yichang, Xiling District, Yichang City, Hubei, China
Sheng Hua Cao Department of General Surgery, Three Gorges University People's Hospital, The First People's Hospital of Yichang, Xiling District, Yichang City, Hubei, China
Yuan Zhang Department of General Surgery, Three Gorges University People's Hospital, The First People's Hospital of Yichang, Xiling District, Yichang City, Hubei, China
Xin Hong Shao Department of General Surgery, Three Gorges University People's Hospital, The First People's Hospital of Yichang, Xiling District, Yichang City, Hubei, China
Abstract
Nedaplatin (NDP) is a second-generation platinum derivative that was developed in Japan. Nowadays, it is being widely used in the management of lung cancer, esophageal cancer, head and neck cancers, especially when cisplatin and carboplatin cannot be tolerated or show drug resistance. To the best of our knowledge, there are few reported cases of NDP-induced bradycardia in the relevant medical literature. The current report presents three patients treated with NDP chemotherapy-induced serious arrhythmias. The three cases developed sinus tachycardia and atrial premature beats, complete left bundle branch block, and bigeminy ventricular premature contraction, in the second, sixth and second cycle, respectively. No one died of cardiac toxicity. These were treated with dexamethasone, 5 mg intravenous injection and diphenhydramine 20 mg, intramuscular injection. The heart rhythm returned to normal in 30 minutes, a day, and four days, respectively.
Publication Details
Page(s) 657-659
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 27, Issue: 10, Year: 2017

Request the full text from PASTIC

Keywords
Nedaplatin. Cardiotoxicity. Arrhythmia. Electrocardiogram. Small cell lung cancer
References
PengPJ,LvBJ,TangC,LiaoH,LinZ,LiuYM, 2015.Phase ii trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma,Drug Des Devel Ther 9 6401 -5
PangH,FengT,LuHL,MengQW,ChenXS,ShenQ, 2016.Efficacy and safety of nedaplatin in advanced breast cancer therapy,Cancer Invest 34 167 -72
WangH,ZhuXL,HuangJ,ChenPS,HanSH,YanX, 2016.Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells,Oncol Lett 11 2566 -72
LiCH,LiuMY,LiuW,LiDD,CaiL, 2014.Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced nonsmall cell lung cancer,Asian Pac J Cancer Prev 15 731 -6
KajiuraS,HosokawaA,YoshitaH,UedaY,UedaA,MiharaH, 2016.Phase I study of docetaxel plus nedaplatin in patients with metastatic or recurrent esophageal squamous cell carcinoma after cisplatin plus 5-fluorouracil treatment,Am J Clin Oncol 39 13 -7
KucharzJ,Michalowska-KaczmarczykA,Zygulska AnetaL,WojtakJ,PawlikW,Herman RomanM, 2016.Bradycardia as a rare symptom of cisplatin cardiotoxicity: A case report,Oncol Lett 11 2297 -9
SchlumbrechtMP,HehrK, 2015.Cisplatin-induced bradycardia and the importance of the QT interval,J Oncol Pharm Pract 21 157 -60
NaitoY,KubotaK,OhmatsuH,GotoK,NihoS,YohK, 2011.Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung,Ann Oncol 22 2471 -5
TakekumaM,HirashimaY,ItoK,TsubamotoH,TabataT,ArakawaA, 2012.Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: A kansai clinical oncology group study,Gynecol Oncol 126 341 -5
CaoW,XuC,LouG,JiangJ,ZhaoS,GengM, 2009.A phase II study of paclitaxel and nedaplatin as frst-line chemotherapy in patients with advanced esophageal cancer,Jpn J Clin Oncol 39 582 -7
0

Citations

0

Downloads

98

Views